Research programme: macrolide antibacterials - Biotica Technology/Pfizer
Latest Information Update: 06 Jun 2007
At a glance
- Originator Biotica Technology; Pfizer
- Mechanism of Action Enzyme modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 06 Jun 2007 Discontinued - Preclinical for Bacterial infections in United Kingdom (unspecified route)